Webinars

Sep 2022

Asia Pacific regional markets, including but not limited to mainland China, Japan, South Korea and Taiwan, play increasingly important roles in global clinical development. Patient-centric endpoints via clinical outcome assessments (COAs) and electronic COAs (eCOAs), are getting more and more attention in clinical research design and execution.

Sponsored by AstraZeneca

Jun 2022

For cancer drugs, payers often prefer to make decisions based on overall survival (OS) outcomes. However, it may take many years to collect OS data; this is particularly apparent in early-stage cancer and when an active therapy is highly effective at extending life.

Sponsored by MDClone

May 2022

Real-world evidence has advanced health research over the past two or three decades. The challenges of procuring sufficient, high-quality real-world data, of unlocking the knowledge contained in the data, and of sharing information without compromising patient privacy are ever-present.

Apr 2022

Speakers will discuss the many uses of COA data gathered during patient-focused drug development, including benefit/risk evaluation, HTA, access decisions, policy decisions, and clinician and patient decision-making.

Sponsored by FIFARMA

Aug 2022

This is the Second webinar of the Value and Access to Innovation webseries sponsored by FIFARMA. The series are structured around FIFARMA's VAI working group workstreams: (1) Funding: what is the relation between health & the economy and how to ensure the long term healthcare system sustainability, (2) Value: what are the value frameworks used by decision makers in LatAm and what is the impact on patient access, (3) Adoption: how to ensure access for the right patient, to the right treatment, at the right time.

Sponsored by FIFARMA

Jul 2022

This is the first webinar of the Value and Access to Innovation webseries sponsored by FIFARMA. The series are structured around FIFARMA's VAI working group workstreams.

Jun 2022

This webinar will aim to provide an educational opportunity for the ISPOR membership to learn about the methods for conducting distributional cost-effectiveness analysis (DCEA).

Sponsored by AstraZeneca

Jun 2022

For cancer drugs, payers often prefer to make decisions based on overall survival (OS) outcomes. However, it may take many years to collect OS data; this is particularly apparent in early-stage cancer and when an active therapy is highly effective at extending life.

Sponsored by Replica Analytics

Sep 2022

Jul 2022

The key success factor for digital health implementation is the information sharing across multiple stakeholders engaged in the clinical decision making. The COVID pandemic revealed numerous differences in how individual data are used in the process of the adoption of various digital health solutions in the healthcare systems across the globe.

Sponsored by MDClone

May 2022

Real-world evidence has advanced health research over the past two or three decades. The challenges of procuring sufficient, high-quality real-world data, of unlocking the knowledge contained in the data, and of sharing information without compromising patient privacy are ever-present.

Sponsored by Biogen

Apr 2022

This session educates about the specific challenges of rare disease treatments in an HTA and discusses how Real-World Evidence Collection can address the data gap at the time of access decision.

Sep 2022

Asia Pacific regional markets, including but not limited to mainland China, Japan, South Korea and Taiwan, play increasingly important roles in global clinical development. Patient-centric endpoints via clinical outcome assessments (COAs) and electronic COAs (eCOAs), are getting more and more attention in clinical research design and execution.

Sep 2022

The webinar will define patient preferences, patient-reported outcomes and patient engagement, by describing their core defining features, how they differ from one another, and outlining the complementary roles that they may have in understanding what matters to patients. The speakers will then discuss how patient preferences, patient-reported outcomes and patient engagement can play a role in marketing authorization and health technology assessment, and ultimately, facilitate better care and access to care for patients.

Sponsored by FIFARMA

Aug 2022

This is the Second webinar of the Value and Access to Innovation webseries sponsored by FIFARMA. The series are structured around FIFARMA's VAI working group workstreams: (1) Funding: what is the relation between health & the economy and how to ensure the long term healthcare system sustainability, (2) Value: what are the value frameworks used by decision makers in LatAm and what is the impact on patient access, (3) Adoption: how to ensure access for the right patient, to the right treatment, at the right time.

Sponsored by AstraZeneca

Jun 2022

For cancer drugs, payers often prefer to make decisions based on overall survival (OS) outcomes. However, it may take many years to collect OS data; this is particularly apparent in early-stage cancer and when an active therapy is highly effective at extending life.

Sponsored by Replica Analytics

Sep 2022

Sponsored by Charles River Associates

Sep 2022

This webinar leverages recent global research conducted across 17 countries to provide an overview of the challenges and solutions to ensure the biosimilar benefits are sustainably delivered to the whole society. There will be a specific focus on the issues in Australia and comparing those against examples found globally. Implications for patients, society as well as a discussion of the learnings in terms of policy provisions and best practices that can help solving these issues will also be held.

Sponsored by FIFARMA

Aug 2022

This is the Second webinar of the Value and Access to Innovation webseries sponsored by FIFARMA. The series are structured around FIFARMA's VAI working group workstreams: (1) Funding: what is the relation between health & the economy and how to ensure the long term healthcare system sustainability, (2) Value: what are the value frameworks used by decision makers in LatAm and what is the impact on patient access, (3) Adoption: how to ensure access for the right patient, to the right treatment, at the right time.

Jul 2022

The key success factor for digital health implementation is the information sharing across multiple stakeholders engaged in the clinical decision making. The COVID pandemic revealed numerous differences in how individual data are used in the process of the adoption of various digital health solutions in the healthcare systems across the globe.

Sponsored by FIFARMA

Aug 2022

This is the Second webinar of the Value and Access to Innovation webseries sponsored by FIFARMA. The series are structured around FIFARMA's VAI working group workstreams: (1) Funding: what is the relation between health & the economy and how to ensure the long term healthcare system sustainability, (2) Value: what are the value frameworks used by decision makers in LatAm and what is the impact on patient access, (3) Adoption: how to ensure access for the right patient, to the right treatment, at the right time.

Sponsored by FIFARMA

Jul 2022

This is the first webinar of the Value and Access to Innovation webseries sponsored by FIFARMA. The series are structured around FIFARMA's VAI working group workstreams.

Sponsored by MDClone

May 2022

Real-world evidence has advanced health research over the past two or three decades. The challenges of procuring sufficient, high-quality real-world data, of unlocking the knowledge contained in the data, and of sharing information without compromising patient privacy are ever-present.

Nov 2020

This capstone webinar culminates the ISPOR-IVI series with a reflection on future direction and commitment needed to improve the scientific credibility and relevance of VA/HTA to pandemic preparedness.

Sep 2021

During this webinar, the speakers will present their respective studies on gene therapy in Duchenne muscular dystrophy, spinal muscular atrophy (SMA) and hemophilia. They will discuss the importance of the disease context, the qualitative research that influenced attribute selection, the selection of health preference method and design of the health preferences’ tasks, and how the study findings relate to the potential value of gene therapy.

Feb 2021

This webinar will present an insightful exchange on best practices, challenges and opportunities for market access of biosimilars in different regions worldwide.

Oct 2020

The webinar will present an overview of societal benefits of biosimilars, how these are measured, how the United States (US) and select markets are tracking in attaining these benefits, and potential solutions for advancing the evidence of potential benefits into action.

Mar 2019

Sponsored by Biogen

Feb 2021

This educational webinar will describe factors that affect the assessment of the clinical and economic value of medical innovations, highlight specific issues with relevance to the societal value of treatments for AD, and place these issues in the context of future health technology assessments for AD treatments.

Dec 2020

This educational webinar explores some of the key issues relating to long-term evidence needs within the context of HTA in AD and considers what can be done in the short, medium, and long term to address evidence needs.

Nov 2020

This webinar will define how Alzheimer’s disease affects underserved communities; share opportunities to create more equitable, ethical, and inclusive value frameworks; and educate on the community’s role in solving this problem.

Oct 2020

This webinar seeks to explore some of these broader elements within the context of evolving value assessment and considers how they may meaningfully be incorporated to facilitate a more holistic approach to valuing medical innovation.